Trending Topics

Chiesi Global Rare Diseases to Focus on Rare Hematology Diseases

Posted on

Chiesi Farmaceutici S.p.A recently launched Chiesi Global Rare Diseases and announced a priority focus on developing therapies for lysosomal storage disorders and rare hematology and ophthalmology disorders. Launched in February 2020, Chiesi Global Rare Diseases also plans to focus on patient advocacy.

“Following the launch of our new rare disease business unit, we were honored to meet with many members of the lysosomal storage disease community at the recent WORLDSymposium meeting in Orlando,” said Giacomo Chiesi, Head of Chiesi Global Rare Diseases in a press release. “The insights we gain from the advocacy community are invaluable and play a key role in helping our team advance important new clinical research and development programs. Our meetings during the WORLDSymposium reflect our broader plans for engagement with many leaders of rare disease communities in the months ahead.

Read the full press release here.

Related Articles
Takeda Demonstrates Ongoing Commitment in Rare Hematology By Continuing to Gather Real-World Evidence and Advance Personalized Treatment
Jun 01, 2021
ASH: Novel Fetal Hemoglobin Repressor for Sickle Cell Disease Identified
May 31, 2020
Education and Support Enhance Care for Rare-Disease Patients
Mar 27, 2020